CTMX in the 13F filings
Cytomx Therapeutics Inc · CUSIP 23284F105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 16
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 1 listed it in both
- Shares listed
- 42,351,165
- combined, among listed positions
- Reported value
- $180m
- combined, at the quarter end
Among the 92 comparable managers: 11 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +7,636,324.
Managers listing CTMX in Q4 2025
16 of 16 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 24,688,109 shares now+9,291,909
- Point72 Asset Management LPexisting position · 5,189,538 shares now+1,120,963
- Two Sigma Investments LPexisting position · 1,560,755 shares now+831,057
- Susquehanna International Group LLPexisting position · 981,598 shares now+714,113
- Two Sigma Advisers LPexisting position · 335,524 shares now+295,524
Reductions
- Citadel Advisors LLCexisting position · 342,304 shares now-1,458,131
- Millennium Management LLCexisting position · 289,653 shares now-1,097,210
- Balyasny Asset Management LLCexisting position · 3,872,202 shares now-40,879
- Invesco Ltdexisting position · 21,976 shares now-450
New positions and exits
Exited (1)
- Renaissance Technologies LLCwas $8.1m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2018 | 3 | $12m | n.a. | n.a. |
| Q2 2018 | 1 | $494k | n.a. | n.a. |
| Q3 2018 | 2 | $27m | n.a. | n.a. |
| Q4 2018 | 2 | $24m | n.a. | n.a. |
| Q1 2019 | 2 | $8.1m | n.a. | n.a. |
| Q2 2019 | 1 | $1.4m | n.a. | n.a. |
| Q3 2019 | 2 | $1.4m | n.a. | n.a. |
| Q4 2019 | 3 | $7.6m | n.a. | n.a. |
| Q1 2020 | 3 | $1.5m | n.a. | n.a. |
| Q2 2020 | 4 | $11m | n.a. | n.a. |
| Q3 2020 | 3 | $5.1m | n.a. | n.a. |
| Q4 2020 | 2 | $1.0m | n.a. | n.a. |
| Q1 2021 | 2 | $56m | n.a. | n.a. |
| Q2 2021 | 2 | $47m | n.a. | n.a. |
| Q3 2021 | 2 | $33m | n.a. | n.a. |
| Q4 2021 | 2 | $28m | n.a. | n.a. |
| Q1 2022 | 1 | $12m | n.a. | n.a. |
| Q3 2022 | 1 | $3.8m | n.a. | n.a. |
| Q4 2022 | 1 | $4.2m | n.a. | n.a. |
| Q2 2023 | 1 | $4.6m | n.a. | n.a. |
| Q1 2024 | 1 | $5.9m | 1 | 0 |
| Q3 2025 | 1 | $7.5m | 1 | 0 |
| Q4 2025 | 1 | $10.0m | 11 | 5 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CTMX and LLY →CTMX and JNJ →CTMX and VRTX →Choose a stock to compare with CTMX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CTMX, latest filings →Back to the 13F Explorer →